Skip to content
Daiichi Sankyo
-
Innovent Biologics to commercialise Daiichi Sankyo’s Vanflyta in China
Vanflyta received approval in China in June 2026 for use in adults with newly diagnosed FLT3-ITD-positive AML, as determined by an appropriate validated diagnostic test.
-
Daiichi Sankyo sells healthcare division to Suntory for USD1.6B in three phases
For Daiichi Sankyo, divesting this business allows the company to concentrate resources on its innovative medicines division, where it has emerged as a leader in antibody-drug conjugate (ADC) technology.
-
China approves Daiichi Sankyo/AstraZeneca’s Enhertu for advanced gastric cancer
The approval specifically targets patients who have already undergone one prior trastuzumab-based treatment regimen.